While different KRAS mutations might have different effects on PPARδ expression, our results show that activation of KRASG12D, the most common KRAS mutation in pancreatic cancer, upregulates PPARδ expression during early pancreatic tumorigenesis not only in in vitro studies, but also, more importantly, in in vivo studies. This evidence concerns the gene KRAS and pancreatic neoplasm.